Press Releases



Dec 18, 2009
Flamel Technologies Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection

Nov 16, 2009
Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million

Nov 04, 2009
Flamel Technologies Announces Licensing Agreement with Pfizer

Nov 04, 2009
Flamel Technologies Announces Projected Release Date of Third Quarter Results; Conference Call

Sep 18, 2009
Flamel Technologies to Present at UBS Global Life Sciences Conference

Aug 05, 2009
Flamel Technologies Announces Second Quarter 2009 Results; Multiple New Projects; Cash Increases from $39.1 to $45.1 million

Jul 28, 2009
Flamel Technologies Announces Projected Release Date of Second Quarter Results; Conference Call

Jul 13, 2009
Baxter and Flamel Technologies Announce Collaboration to Formulate Longer Acting Forms of Blood Clotting Factors

Jun 25, 2009
Flamel Technologies Announces Results of Annual Meeting

Jun 24, 2009
Flamel Technologies Announces Two New Feasibility Agreements

Jun 22, 2009
Flamel Technologies Announces New Feasibility Projects; Technology Access Fee

May 11, 2009
Flamel Technologies Announces Profitable First Quarter Results; Increased Cash Levels

May 05, 2009
Flamel Technologies Announces Projected Release Date of First Quarter Results; Conference Call

Mar 20, 2009
Flamel Technologies to Receive $4 Million Milestone Payment from GlaxoSmithKline

Mar 16, 2009
Flamel Technologies to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston

Mar 04, 2009
Flamel Technologies Announces Fourth Quarter and Year-End 2008 Results

Feb 24, 2009
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results; Conference Call

Feb 23, 2009
Flamel Technologies Announces Appointment of Jeffery S. Vick as Chief Business Officer

Feb 17, 2009
Flamel Technologies Announces Merck Serono's Exercise of Option to License Medusa Technology for Development of an Extended-Release Formulation of a Therapeutic Protein